RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Kintara Therapeutics Stock

Kintara Therapeutics Stocks 2024

Kintara Therapeutics Stocks

26.35 M

Ticker

KTRA

ISIN

US49720K1016

WKN

A2QBU5

In 2024, Kintara Therapeutics had 26.35 M outstanding stocks, a 1,526.67% change from the 1.62 M stocks in the previous year.

The Kintara Therapeutics Stocks history

YEARNUMBER OF STOCKS (undefined USD)
2030e26.35
2029e26.35
2028e26.35
2027e26.35
2026e26.35
2025e26.35
202426.35
20231.62
20220.97
20210.52
20200.21
20190.05
20180.04
20170.02
20160.02
20150.02
20140.8
20130.01
20120.01
20110.01
20100.01
20090.01

Kintara Therapeutics shares outstanding

The number of shares was Kintara Therapeutics in 2023 — This indicates how many shares 1.62 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Kintara Therapeutics earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Kintara Therapeutics's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Kintara Therapeutics’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Kintara Therapeutics's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Kintara Therapeutics Aktienanalyse

What does Kintara Therapeutics do?

Kintara Therapeutics Inc is a US-based biosciences company specializing in the development of cancer drugs and other clinical therapies. It was originally founded as DelMar Pharmaceuticals in 2008 before being renamed Kintara Therapeutics in 2019. The company focuses on developing drugs for the treatment of severe types of cancer such as glioblastoma, a particularly aggressive form of brain tumors. In addition, Kintara Therapeutics also develops clinical therapies for a broader range of indications, including breast cancer and lung cancer. Kintara Therapeutics has developed a proprietary technology platform called VAL-083, which is based on the effect of a chemical compound called dianhydrogalactitol (DAG). VAL-083 is being investigated as a potential treatment for various types of cancer, including those that have become resistant to other therapies. VAL-083 has received orphan drug designation status in the United States and Europe. This means that it is considered a promising new therapy for rare and serious diseases, allowing Kintara Therapeutics to have a faster approval process. In addition to the development of VAL-083, Kintara Therapeutics is also conducting a number of clinical trials on other drug candidates in its pipeline. This includes REM-001, a novel photoimmunotherapy drug for the treatment of cutaneous T-cell lymphomas. REM-001 is based on the use of light and a special type of antibodies to selectively destroy cancer cells. Another important area of business for Kintara Therapeutics is academic collaboration. The company works closely with academic institutions such as the Mayo Clinic, Duke University, and the University of California (San Francisco) to develop and test potential therapies. In addition, Kintara Therapeutics has also partnered with IQVIA, a leading provider of clinical study services, in order to achieve optimal results. In addition to the development and commercialization of cancer drugs, Kintara Therapeutics is also committed to responsible corporate governance. The company is dedicated to having a positive impact on patients, healthcare, and society as a whole through its products and business practices. Overall, Kintara Therapeutics has established a reputation as a reliable partner for the development of cancer therapies and other clinical therapies. The company has a strong portfolio of drug candidates and a broad base for collaborations to unleash its potential in healthcare. Kintara Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Stocks Details

Evaluating Kintara Therapeutics's Shares Outstanding

Kintara Therapeutics's shares outstanding refer to the total number of shares that are currently held by all its shareholders, including institutional investors and restricted shares held by the company’s officers and insiders. The number of shares outstanding is crucial in determining the company's market capitalization and is used by investors to assess the company’s size, financial health, and investment potential.

Year-to-Year Comparison

Tracking the changes in Kintara Therapeutics’s shares outstanding over the years can provide investors with insights into the company's financial strategies and market valuation. An increase in shares outstanding can result from actions like issuing new shares, while a decrease can result from buybacks.

Impact on Investments

For investors, understanding Kintara Therapeutics’s shares outstanding is essential for evaluating its earnings per share (EPS) and market valuation. A change in the number of shares outstanding can impact the EPS, which is a significant driver of stock prices and investor decisions.

Interpreting Changes in Shares Outstanding

Variances in Kintara Therapeutics’s shares outstanding can signal shifts in the company’s financial strategy. An increase may dilute the EPS and share value, indicating potential fundraising or acquisitions. Conversely, a decrease, often due to share buybacks, can enhance share value and indicate the company’s confidence in its financial performance.

Frequently Asked Questions about Kintara Therapeutics stock

How many stocks are there of Kintara Therapeutics?

The current number of stocks of Kintara Therapeutics is 26.35 M undefined.

What does Number of Shares / OutstandingShares mean?

The outstanding shares (or issued shares) of Kintara Therapeutics are the total number of shares issued and actively held by shareholders - both external investors and company insiders. However, these must be actual shares. may grant stock options to executives that can be converted into shares.

How has the number of shares of Kintara Therapeutics evolved in recent years?

The number of shares of Kintara Therapeutics has increased by 1,526.67% gestiegen compared to last year.

What does the number of shares mean for investors?

The number of shares outstanding is used to calculate key metrics such as a company's market capitalization, earnings per share (EPS), and cash flow per share (CFPS). The number of outstanding shares of a company is not static and can fluctuate greatly over time.

Why does the number of stocks fluctuate?

There are various factors that can lead to a change. Kintara Therapeutics as a company can issue new shares, carry out stock splits or reverse splits.

Does the number of shares have an impact on the performance of Kintara Therapeutics?

There is no tangible long-term evidence or study that stocks with a certain number of shares (regardless of Mega/Large/Mid/Small Cap) would yield significantly higher returns than others. There are occasional small studies (limited number of stocks, short investment period) that certain classes outperform or have higher risk, but none of them are 1. conclusive (cause-effect is unclear, experiment is not repeatable) or 2. generalizable (generalization is not possible due to small sample size and time period).

How much dividend does Kintara Therapeutics pay?

Over the past 12 months, Kintara Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Kintara Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Kintara Therapeutics?

The current dividend yield of Kintara Therapeutics is .

When does Kintara Therapeutics pay dividends?

Kintara Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Kintara Therapeutics?

Kintara Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Kintara Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Kintara Therapeutics located?

Kintara Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Kintara Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Kintara Therapeutics from 11/20/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 11/20/2024.

When did Kintara Therapeutics pay the last dividend?

The last dividend was paid out on 11/20/2024.

What was the dividend of Kintara Therapeutics in the year 2023?

In the year 2023, Kintara Therapeutics distributed 0 USD as dividends.

In which currency does Kintara Therapeutics pay out the dividend?

The dividends of Kintara Therapeutics are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Kintara Therapeutics

Our stock analysis for Kintara Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Kintara Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.